Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2014

Autores

Lima, A (Autor) Outra; Sousa, H (Autor) Outra; Monteiro, J (Autor) Outra; Azevedo, R (Autor) Outra; Rui Medeiros (Autor) ICBAS; Seabra, V (Autor) Outra

Revista

Título: Pharmacogenomics

Vol. 15

Páginas: 1611-1635

ISSN: 1462-2416

Editora: ASHLEY PUBLICATIONS LTD

Indexação

ISI Web of Knowledge - 15 Citações

Scopus - 18 Citações

Outras Informações

ID Authenticus: P-009-WRC

DOI: 10.2217/pgs.14.116

Abstract (EN): Methotrexate (MTX) is used in low doses to treat a variety of diseases. Although the mechanism responsible for its therapeutic action is unknown, MTX membrane transport proteins (influx and/or efflux) can be major determinants of pharmacokinetics, adverse drug reactions and clinical response profiles. With progess in pharmacogenomics, the improvement of the prediction of patients' therapeutic outcome treated with low doses of MTX will offer a powerful tool for the translation of transporter SNPs into clinical practice and will be essential to sustain a breakthrough in the field of personalized medicine. Therefore, this paper provides an update on the current data on SNPs in genes encoding low-dose MTX membrane transport proteins and their relevance as possible biomarkers of MTX therapeutic outcome.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 25